Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX LM W DEXTROSE 4 25 IN PLASTIC CONTAINER versus EXTRANEAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX LM W DEXTROSE 4 25 IN PLASTIC CONTAINER versus EXTRANEAL.
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER vs EXTRANEAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intraperitoneal administration of hypertonic dextrose solution creates an osmotic gradient across the peritoneal membrane, facilitating ultrafiltration and removal of uremic toxins through peritoneal dialysis.
Extraneal (icodextrin) is a glucose polymer that acts as an osmotic agent for peritoneal dialysis. It is absorbed from the peritoneal cavity into the bloodstream and metabolized to maltose and other oligosaccharides. Its primary mechanism is to create an osmotic gradient across the peritoneal membrane, facilitating ultrafiltration and removal of waste products.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, or as prescribed for continuous ambulatory peritoneal dialysis (CAPD); may adjust volume and frequency based on patient's fluid and electrolyte status.
7.5% solution: 2 L intraperitoneally, dwell time 4–8 hours, up to 4 exchanges per day. For automated peritoneal dialysis: 2 L per cycle, typically 3–5 cycles overnight.
None Documented
None Documented
Dextrose terminal half-life is approximately 1-2 hours in normal metabolism; in peritoneal dialysis, continuous removal leads to variable half-life depending on dwell time and ultrafiltration; clinical context: continuous exposure during dwell.
The terminal elimination half-life of icodextrin in plasma is approximately 19 hours (range 12-22 hours) following intraperitoneal administration for a dwell of 8-12 hours. This long half-life reflects slow metabolism and clearance, particularly relevant in patients with impaired renal function, leading to accumulation of maltose and other oligosaccharides.
Peritoneal dialysis solution; dextrose is metabolized and eliminated via peritoneal dialysis; approximately 70-80% of dextrose is absorbed systemically and metabolized; the non-absorbed fraction is removed with dialysate outflow; lactate (buffer) is converted to bicarbonate in the liver and eliminated via respiration and urine.
Icodextrin is metabolized to maltose, maltotriose, and other oligosaccharides. After intraperitoneal administration, approximately 40% of the administered dose is absorbed systemically; the absorbed icodextrin and its metabolites are primarily eliminated by renal excretion (via glomerular filtration). In patients with residual renal function, approximately 30-40% of the absorbed dose is excreted in urine over 14 days. Biliary/fecal excretion is negligible (<1%).
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution